This secondary analysis of a randomized clinical trial examines the risk of kidney or hepatic toxic effects among patients with impaired kidney function at baseline treated with remdesivir. Click to show full abstract
This secondary analysis of a randomized clinical trial examines the risk of kidney or hepatic toxic effects among patients with impaired kidney function at baseline treated with remdesivir.
               
Click one of the above tabs to view related content.